Recurrence risk factors were assessed using log-rank test, and survival probabilities were estimated with Kaplan-Meier analysis.<h4>Results</h4>Of 180 patients with hormone receptor (HR)-positive pure DCIS treated with mastectomy, 120 (66.7%) received tamoxifen, while the remaining 60 (33.3%) did not. Here, NR4A1 is linked to ductal breast carcinoma in situ.